Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Larimar TherapeuticsLRMR | Open-market buy | 02/27 | 03/02 | 5,000,000 sh4 trades | $5.00avg. | $25,000,000 | +413.9% | |
Jeffrey W. ShermanDirector | Larimar TherapeuticsLRMR | Open-market buy | 02/27 | 03/02 | 5,000 sh | $5.00 | $25,000 | No record |
Frank E. ThomasDirector | Larimar TherapeuticsLRMR | Open-market buy | 02/27 | 03/02 | 5,000 sh | $5.00 | $25,000 | +250.0% |
Thomas Edward HamiltonDirector | Larimar TherapeuticsLRMR | Open-market buy | 02/27 | 03/02 | 100,000 sh | $5.00 | $500,000 | +17.7% |
Larimar TherapeuticsLRMR | Open-market buy | 25/07/31 | 25/08/04 | 9,375,000 sh3 trades | $3.20avg. | $30,000,000 | No record | |
Thomas Edward HamiltonDirector | Larimar TherapeuticsLRMR | Open-market buy | 24/02/16 | 24/05/31 | 57,208 sh | $8.74 | $499,997.92 | +11.3% |
Larimar TherapeuticsLRMR | Open-market buy | 24/02/16 | 24/02/16 | 4,290,617 sh3 trades | $8.74avg. | $37,499,992.58 | No record | |
Frank E. ThomasDirector | Larimar TherapeuticsLRMR | Open-market buy | 24/02/14 | 24/02/15 | 2,000 sh | $11.00 | $22,000 | No record |
Gopi ShankarChief Development Officer | Larimar TherapeuticsLRMR | Open-market buy | 23/12/07 | 23/12/08 | 5,000 sh | $3.73 | $18,650 | No record |
Larimar TherapeuticsLRMR | Open-market buy | 23/05/17 | 23/05/18 | 5,000 sh | $3.73 | $18,650 | +4.6% | |
Joseph TruittDirector | Larimar TherapeuticsLRMR | Open-market buy | 23/05/17 | 23/05/18 | 2,750 sh | $3.73 | $10,257.5 | No record |
Carole Ben-MaimonPresident and CEO | Larimar TherapeuticsLRMR | Open-market buy | 23/05/17 | 23/05/18 | 5,000 sh | $3.71 | $18,550 | +1.9% |